<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01141205</url>
  </required_header>
  <id_info>
    <org_study_id>HIV-BIS NCP03/2009</org_study_id>
    <secondary_id>EDCTP_MSI.2009.10800.001</secondary_id>
    <nct_id>NCT01141205</nct_id>
  </id_info>
  <brief_title>HIV-1 Peptide Immunisation of Individuals in West Africa to Prevent Disease</brief_title>
  <acronym>HIV-BIS</acronym>
  <official_title>Phase I Study: HIV-1 Peptide Immunisation of Individuals in West Africa to Prevent Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Statens Serum Institut</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of the Interior and Health, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>European and Developing Countries Clinical Trials Partnership (EDCTP)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Statens Serum Institut</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Treatment: Immunization with peptide-mix and adjuvant. The vaccine should induce cellular
      immunity against HIV-1.

      Target group: Untreated healthy individuals with chronic HIV-1 infection.

      Purpose: The primary purpose is to evaluate tolerability and safety of the vaccine.

      The secondary purpose is to evaluate the clinical effect of the vaccination treatment as
      measured by induction of immunity, lowering of viral load, induction of escape mutations in
      the virus and improvement in the patient CD4 lymphocyte blood counts.

      The third purpose is to evaluate the feasibility of conducting a therapeutic HIV immunization
      study in a poorly-resourced African setting.

      Design: The experiment is designed as a blinded, placebo-controlled phase 1 clinical trial in
      HIV-1 infected individuals in West Africa.

      Numbers of individuals: Phase I: 20 fully evaluable HIV-1-infected patients should enter the
      study (15 vaccine treated and 5 placebo(saline) treated controls).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The HIV infection does not leave lifelong immunity, but leads to break down of the immune
      system, opportunistic infections and death. The immunity obtained by the infection itself can
      only partially contain the HIV infection. The purpose with a targeted therapeutic vaccination
      is therefore in addition to the existing immunity to induce a broader, more powerful and more
      rationally or better directed immunity than the one induced by the &quot;natural&quot; HIV-1 infection.
      This would potentially lower the viral load in the blood making it more difficult to spread
      the virus to others and prolong the time to AIDS disease and medical treatment. There is a
      need for new rational vaccination possibilities, able to prevent (HIV) disease, postpone the
      need for antiretroviral medical treatment, prolong the life, and limit spread of HIV-1 in the
      population. The present protocol seak to introduce such a new immune treatment principle for
      HIV-1 infected individuals. In this study, individuals with chronic HIV-1 infection will be
      vaccinated with selected synthetic HIV immune-peptides representing new discovered conserved
      target´s on the virus. The vaccine should induce new immunity against several epitope targets
      on their HIV, whereby the HIV infection may be controlled for a longer time by the immune
      system. The purpose of the study is primarily to evaluate the safety and tolerability of the
      vaccine and secondary to evaluate the immunological and antiviral response in the vaccinated
      individuals.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2009</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tolerability and Safety of the Treatment.</measure>
    <time_frame>up to 6 months after end of treatment</time_frame>
    <description>We report here the numbers of participants with vaccine related adverse events degree 3 or 4.
Our goal for safety and tolerability was: &quot;Fewer than or 3 patients of the 15 vaccine treated show treatment related (reaction 3) side-effects of degree 3 or 4&quot;.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Induction of New T-cell Immune Response by the Vaccine</measure>
    <time_frame>up to 6 months after last immunisation</time_frame>
    <description>induction of new T-cell immune response against one or more of the vaccine epitopes using Interferon gamma Enzyme Linked Immuno spot assay (IFNg-ELISPOT assay)measuring Spot forming Unis per 1 million periferal blood mononuclear cells (SFU/1 mio PBMCs) above treshold (&gt; 50 sfu/mio PBMC).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lowering of HIV-1 RNA Viral-load in HIV-1 Immune Responders More Than 1 Log</measure>
    <time_frame>up to 6 months post immunization</time_frame>
    <description>changes (lowering) in Plasma HIV-1 RNA viral-load (measured by Quantitative RT-PCR kit, ROCHE) of more than 1 log</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Increase in Blood CD4 T-cell Counts</measure>
    <time_frame>up to 6 months post vaccination</time_frame>
    <description>Analyzed: Participants (minus drop-outs and withdrawn) with measured blood CD4 T-cell counts (cells/microliter). Reported: Numbers of participants obtaining an increase in measured blood CD4 T-cell counts post vaccination of &gt;100 CD4 Tcell per microliter</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Aids, Cdc Group I</condition>
  <arm_group>
    <arm_group_label>AFO-18</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>18 peptides representing CD8 and CD4 epitopes mainly on HIV-1 in an adjuvants (CAF01)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AFO-18</intervention_name>
    <description>18 peptides representing CD8 and CD4 epitopes mainly on HIV-1 in an adjuvants (CAF01)</description>
    <arm_group_label>AFO-18</arm_group_label>
    <other_name>CAF01</other_name>
    <other_name>HIV-1 peptides</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>1.2 ml saline intramuscularly</description>
    <arm_group_label>Saline</arm_group_label>
    <other_name>NaCl</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. HIV-1 seropositive with measurable viral load &gt;10e3 copies/ml and CD4+ T-cell count
             &gt;400 CD4+ cells/µl.

          2. Not in Antiretroviral Therapy (&gt;1 year).

          3. Male or female with age between 18 and 50 years.

          4. Normal values for the area of liver and kidney enzymes, blood cell count with
             differential counts (e.g. white blood cells, lymphocytes, platelets/thrombocytes) and
             Hemoglobin

          5. Expected to follow the instructions.

          6. Written informed consent after oral and written information.

        Exclusion Criteria:

          1. Vaccinated with other vaccines within 3 months before the first vaccination.

          2. Treated with immune modulating medicine within 3 month before the first immunization.

          3. Other important active chronic infectious diseases likely to influence the HIV-1
             infection, like HIV-2, HBV, HCV and TB

          4. Significant medical disease as judged by the investigators, for example severe
             asthma/COLD, badly regulated heart disease, insulin-dependent diabetes mellitus.

          5. Severe allergy or earlier anaphylactic reactions.

          6. Active autoimmune diseases.

          7. Simultaneous treatment with other experimental drugs.

          8. Laboratory parameters outside the 'normal' range for the area and which are considered
             clinically significant.

          9. Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anders Fomsgaard, DMSc</last_name>
    <role>Study Director</role>
    <affiliation>Statens Serum Institut</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Zacarias Jose da Silva, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bandim Health Project, Bissau, Guinea-Bissau</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Nacional Simao Mendes</name>
      <address>
        <city>Bissau</city>
        <country>Guinea-Bissau</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Guinea-Bissau</country>
  </location_countries>
  <results_reference>
    <citation>Román VR, Jensen KJ, Jensen SS, Leo-Hansen C, Jespersen S, da Silva Té D, Rodrigues CM, Janitzek CM, Vinner L, Katzenstein TL, Andersen P, Kromann I, Andreasen LV, Karlsson I, Fomsgaard A. Therapeutic vaccination using cationic liposome-adjuvanted HIV type 1 peptides representing HLA-supertype-restricted subdominant T cell epitopes: safety, immunogenicity, and feasibility in Guinea-Bissau. AIDS Res Hum Retroviruses. 2013 Nov;29(11):1504-12. doi: 10.1089/AID.2013.0076. Epub 2013 Jun 21.</citation>
    <PMID>23634822</PMID>
  </results_reference>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 9, 2010</study_first_submitted>
  <study_first_submitted_qc>June 9, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 10, 2010</study_first_posted>
  <results_first_submitted>June 13, 2012</results_first_submitted>
  <results_first_submitted_qc>September 13, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 15, 2012</results_first_posted>
  <last_update_submitted>August 2, 2013</last_update_submitted>
  <last_update_submitted_qc>August 2, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 8, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Statens Serum Institut</investigator_affiliation>
    <investigator_full_name>Anders Fomsgaard</investigator_full_name>
    <investigator_title>Chief Medical Doctor</investigator_title>
  </responsible_party>
  <keyword>AIDS vaccines</keyword>
  <keyword>HIV-1 vaccine</keyword>
  <keyword>Therapeutic vaccine</keyword>
  <keyword>Cellular immunity</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>medical clinic</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>AFO-18</title>
          <description>18 peptides representing 15 CD8 and 3 CD4 epitopes on HIV-1 plus 1 CD4 T helper epitope unrelated to HIV in an adjuvant (CAF01). Total 4.5 mg peptide (250 micro gram of each peptide) in CAF01 adjuvant. Total volume of 1.25 ml was injected i.m. (in m. deltoideus) at weeks 0, 2, 4, 8</description>
        </group>
        <group group_id="P2">
          <title>Saline</title>
          <description>Placebo was Sterile saline injection, 1.25 ml i.m. (in m. deltoideus) at each vaccination weeks 0, 2, 4, 8</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>AFO-18</title>
          <description>18 peptides representing CD8 and CD4 epitopes mainly on HIV-1 in an adjuvants (CAF01)</description>
        </group>
        <group group_id="B2">
          <title>Saline</title>
          <description>Saline injection</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="18"/>
            <count group_id="B2" value="5"/>
            <count group_id="B3" value="23"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34" spread="2"/>
                    <measurement group_id="B2" value="29" spread="2"/>
                    <measurement group_id="B3" value="32" spread="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Guinea-Bissau</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Tolerability and Safety of the Treatment.</title>
        <description>We report here the numbers of participants with vaccine related adverse events degree 3 or 4.
Our goal for safety and tolerability was: &quot;Fewer than or 3 patients of the 15 vaccine treated show treatment related (reaction 3) side-effects of degree 3 or 4&quot;.</description>
        <time_frame>up to 6 months after end of treatment</time_frame>
        <population>Analyzed: number of participants started minus individuals lost to follow up or participants that withdraw. Thus we include the two individuals where the physician stopped his/her participation because of SAE not related to the vaccine or to the placebo. Reported: numbers of participants with vaccina related SAE</population>
        <group_list>
          <group group_id="O1">
            <title>Vaccinee</title>
            <description>participants receiving active peptide in CAF01 adjuvants vaccine</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>participants receiving saline</description>
          </group>
        </group_list>
        <measure>
          <title>Tolerability and Safety of the Treatment.</title>
          <description>We report here the numbers of participants with vaccine related adverse events degree 3 or 4.
Our goal for safety and tolerability was: &quot;Fewer than or 3 patients of the 15 vaccine treated show treatment related (reaction 3) side-effects of degree 3 or 4&quot;.</description>
          <population>Analyzed: number of participants started minus individuals lost to follow up or participants that withdraw. Thus we include the two individuals where the physician stopped his/her participation because of SAE not related to the vaccine or to the placebo. Reported: numbers of participants with vaccina related SAE</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Induction of New T-cell Immune Response by the Vaccine</title>
        <description>induction of new T-cell immune response against one or more of the vaccine epitopes using Interferon gamma Enzyme Linked Immuno spot assay (IFNg-ELISPOT assay)measuring Spot forming Unis per 1 million periferal blood mononuclear cells (SFU/1 mio PBMCs) above treshold (&gt; 50 sfu/mio PBMC).</description>
        <time_frame>up to 6 months after last immunisation</time_frame>
        <population>Analyzed: Participants minus drop-outs and withdrawn participants. Reported: numbers of participants with a new induced ELISPOT Y-cell immune response to the vaccine peptide epitopes</population>
        <group_list>
          <group group_id="O1">
            <title>AFO-18</title>
            <description>18 peptides representing CD8 and CD4 epitopes mainly on HIV-1 in an adjuvants (CAF01)</description>
          </group>
          <group group_id="O2">
            <title>Placebo Saline</title>
            <description>Saline injection</description>
          </group>
        </group_list>
        <measure>
          <title>Induction of New T-cell Immune Response by the Vaccine</title>
          <description>induction of new T-cell immune response against one or more of the vaccine epitopes using Interferon gamma Enzyme Linked Immuno spot assay (IFNg-ELISPOT assay)measuring Spot forming Unis per 1 million periferal blood mononuclear cells (SFU/1 mio PBMCs) above treshold (&gt; 50 sfu/mio PBMC).</description>
          <population>Analyzed: Participants minus drop-outs and withdrawn participants. Reported: numbers of participants with a new induced ELISPOT Y-cell immune response to the vaccine peptide epitopes</population>
          <units>ELISPOT responders</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lowering of HIV-1 RNA Viral-load in HIV-1 Immune Responders More Than 1 Log</title>
        <description>changes (lowering) in Plasma HIV-1 RNA viral-load (measured by Quantitative RT-PCR kit, ROCHE) of more than 1 log</description>
        <time_frame>up to 6 months post immunization</time_frame>
        <population>Participants minus drop outs and participants withdrawn by them selves or by the physicians</population>
        <group_list>
          <group group_id="O1">
            <title>Vaccinee</title>
            <description>participants receiving active HIV-1 peptide vaccine in CAF01 adjuvant i.m.</description>
          </group>
          <group group_id="O2">
            <title>Saline</title>
            <description>Placebo participants receiving sterile saline i.m.</description>
          </group>
        </group_list>
        <measure>
          <title>Lowering of HIV-1 RNA Viral-load in HIV-1 Immune Responders More Than 1 Log</title>
          <description>changes (lowering) in Plasma HIV-1 RNA viral-load (measured by Quantitative RT-PCR kit, ROCHE) of more than 1 log</description>
          <population>Participants minus drop outs and participants withdrawn by them selves or by the physicians</population>
          <units>participants with lowering of VL</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Increase in Blood CD4 T-cell Counts</title>
        <description>Analyzed: Participants (minus drop-outs and withdrawn) with measured blood CD4 T-cell counts (cells/microliter). Reported: Numbers of participants obtaining an increase in measured blood CD4 T-cell counts post vaccination of &gt;100 CD4 Tcell per microliter</description>
        <time_frame>up to 6 months post vaccination</time_frame>
        <population>Participants minus drop-outs and withdrawn participants</population>
        <group_list>
          <group group_id="O1">
            <title>Vaccinee</title>
            <description>participants receiving active peptide in CAF01 adjuvants vaccine</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>participants receiving saline</description>
          </group>
        </group_list>
        <measure>
          <title>Increase in Blood CD4 T-cell Counts</title>
          <description>Analyzed: Participants (minus drop-outs and withdrawn) with measured blood CD4 T-cell counts (cells/microliter). Reported: Numbers of participants obtaining an increase in measured blood CD4 T-cell counts post vaccination of &gt;100 CD4 Tcell per microliter</description>
          <population>Participants minus drop-outs and withdrawn participants</population>
          <units>participants with increased CD4 count</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <desc>One participant in the vaccinee group of 18 individuals had a SAE (serious infection) not related to the vaccine. One participant in the saline placebo group of 5 individuals experienced a SAE (increase in liver enzymes) not related to the placebo saline.
None others experienced any AE was noted.</desc>
      <group_list>
        <group group_id="E1">
          <title>AFO-18</title>
          <description>18 peptides representing CD8 and CD4 epitopes mainly on HIV-1 in an adjuvants (CAF01)</description>
        </group>
        <group group_id="E2">
          <title>Saline</title>
          <description>Saline injection</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Died of pneumonia</sub_title>
                <description>One participant died of severe gastroenteritis and pneumonia unrelated to the vaccine</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Increase in liver enzymes</sub_title>
                <description>One placebo (saline) participant got elevation of liverenzymes (unrelated to the placebo)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Anders Fomsgaard</name_or_title>
      <organization>Statens Serum Institut</organization>
      <phone>+45-32683460</phone>
      <email>afo@ssi.dk</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

